Assignee
CELLECTIS
FR·80 granted patents·84 pending applications·457 citations·filing 2002–2025
Top patents by PatentIndex Score
164 records- 0198US10584352B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2018·Granted Mar 10, 2020·21 cites·20 claims
- 0298US9855297B2Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease systemCELLECTIS·Filed 2016·Granted Jan 2, 2018·50 cites·17 claims
- 0397US10870864B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2020·Granted Dec 22, 2020·4 cites·18 claims
- 0497US9890393B2Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease systemCELLECTIS·Filed 2014·Granted Feb 13, 2018·38 cites·3 claims
- 0596US11077144B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2020·Granted Aug 3, 2021·7 cites·17 claims
- 0696US9944702B2CD33 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Apr 17, 2018·29 cites·29 claims
- 0795US10286007B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2017·Granted May 14, 2019·12 cites·18 claims
- 0895US9944709B2CD123 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Apr 17, 2018·21 cites·19 claims
- 0995US7897372B2I-CreI meganuclease variants with modified specificity, method of preparation and uses thereofCELLECTIS·Filed 2006·Granted Mar 1, 2011·42 cites·54 claims
- 1095US7842489B2Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereofCELLECTIS·Filed 2010·Granted Nov 30, 2010·63 cites·7 claims
- 1194US11274316B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2021·Granted Mar 15, 2022·2 cites·5 claims
- 1294US10874693B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2014·Granted Dec 29, 2020·7 cites·11 claims
- 1393US10752684B2ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Aug 25, 2020·12 cites·10 claims
- 1493US10196608B2Method for in situ inhibition of regulatory T cellsCELLECTIS·Filed 2015·Granted Feb 5, 2019·8 cites·16 claims
- 1592US10836998B2Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cellsCELLECTIS·Filed 2015·Granted Nov 17, 2020·5 cites·26 claims
- 1691US10759868B2Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Sep 1, 2020·6 cites·8 claims
- 1791US10363270B2Methods for engineering allogeneic and immunosuppressive resistant T cell immunotherapyCELLECTIS·Filed 2017·Granted Jul 30, 2019·6 cites·7 claims
- 1891US10316101B2BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Jun 11, 2019·11 cites·20 claims
- 1990US10426795B2Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cellsCELLECTIS·Filed 2013·Granted Oct 1, 2019·8 cites·17 claims
- 2089US11186824B2Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patientsCELLECTIS·Filed 2016·Granted Nov 30, 2021·4 cites·22 claims
- 2189US10239948B2Method of engineering multi-input signal sensitive T cell for immunotherapyCELLECTIS·Filed 2014·Granted Mar 26, 2019·16 cites·9 claims
- 2289US2024309397A1Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapyCELLECTIS·Filed 2023·Application pending·0 cites
- 2388US10709775B2Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivationCELLECTIS·Filed 2016·Granted Jul 14, 2020·7 cites·15 claims
- 2488US10378026B2RNA based method to obtain stably integrated retroviral vectorsCELLECTIS·Filed 2014·Granted Aug 13, 2019·6 cites·11 claims
- 2588US10006052B2Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereofCELLECTIS·Filed 2014·Granted Jun 26, 2018·17 cites·14 claims
- 2687US11304975B2Methods for engineering allogeneic and highly active t cell for immunotherapyCELLECTIS·Filed 2014·Granted Apr 19, 2022·4 cites·6 claims
- 2787US10342829B2Multi-chain chimeric antigen receptor and uses thereofCELLECTIS·Filed 2013·Granted Jul 9, 2019·6 cites·6 claims
- 2886US12252699B2Method for generating t-cells compatible for allogenic transplantationCELLECTIS·Filed 2023·Granted Mar 18, 2025·0 cites·12 claims
- 2986US11891614B2Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapyCELLECTIS·Filed 2020·Granted Feb 6, 2024·1 cites·16 claims
- 3086US10517896B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2019·Granted Dec 31, 2019·2 cites·19 claims
- 3185US12577581B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2022·Granted Mar 17, 2026·0 cites·9 claims
- 3285US11466291B2Sequential gene editing in primary immune cellsCELLECTIS·Filed 2017·Granted Oct 11, 2022·4 cites·27 claims
- 3385US11014989B2Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapyCELLECTIS·Filed 2016·Granted May 25, 2021·2 cites·24 claims
- 3485US10472613B2Method for modulating car-induced immune cells activityCELLECTIS·Filed 2015·Granted Nov 12, 2019·6 cites·29 claims
- 3583US10113162B2Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genesCELLECTIS·Filed 2014·Granted Oct 30, 2018·6 cites·13 claims
- 3682US2022177914A1Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cellsCELLECTIS·Filed 2022·Application pending·0 cites
- 3782US2025188483A1Methods for non-transgenic genome editing in plantsCELLECTIS·Filed 2024·Application pending·0 cites
- 3881US10087453B2Modified diatoms for biofuel productionCELLECTIS·Filed 2014·Granted Oct 2, 2018·4 cites·20 claims
- 3980US12391933B2Targeted gene insertion for improved immune cells therapyCELLECTIS·Filed 2023·Granted Aug 19, 2025·0 cites·15 claims
- 4080US9365864B2Meganuclease recombination systemCELLECTIS·Filed 2013·Granted Jun 14, 2016·3 cites·19 claims
- 4179US11674155B2Sequential gene editing in primary immune cellsCELLECTIS·Filed 2022·Granted Jun 13, 2023·0 cites·17 claims
- 4279US11498971B2BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2019·Granted Nov 15, 2022·1 cites·26 claims
- 4379US11414674B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2019·Granted Aug 16, 2022·0 cites·10 claims
- 4478US2023357719A1Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cellsCELLECTIS·Filed 2023·Application pending·0 cites
- 4577US11311575B2Methods for engineering highly active T cell for immunotherapyCELLECTIS·Filed 2014·Granted Apr 26, 2022·1 cites·15 claims
- 4677US11007224B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2020·Granted May 18, 2021·0 cites·10 claims
- 4776US10988541B2CD123 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2018·Granted Apr 27, 2021·1 cites·18 claims
- 4876US2023287454A1Sequential gene editing in primary immune cellsCELLECTIS·Filed 2023·Application pending·0 cites
- 4976US2024182565A1Cd33 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2023·Application pending·0 cites
- 5075US11959091B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2020·Granted Apr 16, 2024·0 cites·21 claims
Showing the top 50 of 164 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →